Source: Eur Respir J 2011; 37: 9-11



Rating:

Share or cite this content

Citations should be made in the following way:
Woodhead M.. Prescribing and guidelines: both must improve to combat antimicrobial resistance. Eur Respir J 2011; 37: 9-11

Member's Comments

No comment yet.

Related content which might interest you: Stewardship programmes to decrease antibiotic resistance and to improve outcomes Source: International Congress 2018 – New Sepsis Surviving Campaign guidelines: back to the “art of medicine” Year: 2018 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Point of care respiratory viral testing (POCT): A novel service to target appropriate antimicrobial prescription and improve antibiotic stewardship. Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Antibiotic management and resistance Source: Eur Respir Monogr 2018; 81: 312-330 Year: 2018 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 International guidelines for nosocomial pneumonia: do they cover multidrug resistance management? Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution Year: 2019 Preventing and managing antimicrobial resistance: imperative for chest physicians Source: Eur Respir J 2011; 37: 978-981 Year: 2011 A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics? Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Rational use and stewardship of antibiotics in pediatric respiratory disease Source: ERS Courses: Paediatric respiratory infections Year: 2019 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 How to build an antimicrobial stewardship programme Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 How to link antimicrobial and diagnostic stewardship Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021 Predicting outcomes and drug resistance with new standardised treatment Source: Eur Respir J 2011; 37: 974 Year: 2011